

## Special Issue

# Quantitative Technologies to Decipher Functional Phenotypes of Tumor-Associated Macrophages

### Message from the Guest Editor

In majority of solid tumor tumor-associated macrophages (TAMs) have predominant pro-tumor activity, TAMs are highly heterogenous and can support tumor by multiple mechanisms, including epigenetic, transcriptional and metabolic. In contrast, in some tumors, where colorectal cancer is the most striking example, total amount of TAMs correlates with good prognosis. In other tumors, like breast cancer subpopulations of TAMs correlate with decreased metastatic rate. Our Special issue is dedicated to quantitative approaches that allow to decipher pro- and anti-tumor programming and functions of TAMs and their circulating precursors monocyte in solid cancers. Such technologies include but are not restricted to quantitative immunohistology/confocal microscopy, single cell analytics, spatial transcriptomics and mass-spectrometric metabolomics. We look forward to receiving your contributions.

---

### Guest Editor

Dr. Julia Kzhyshkowska

Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany

---

### Deadline for manuscript submissions

closed (15 October 2023)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/156213](https://mdpi.com/si/156213)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)